RHYTHM PHARMACEUTICALS INC

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)


· · March 31, · · December 31,
	2025		2024

Assets
Current assets: · ·
Cash and cash equivalents		$106,095		$89,137
Short-term investments		208,393		231,428
Accounts receivable, net		17,825		18,512
Inventory		19,316		18,741
Prepaid expenses and other current assets		17,659		16,382
Total current assets		369,288		374,200
Property and equipment, net		462		632
Right-of-use asset		3,367		3,477
Intangible assets, net		5,960		6,174
Restricted cash		464		464
Other long-term assets		7,144		7,326
Total assets		$386,685		$392,273
Liabilities, Convertible Preferred Stock and Stockholders’ equity
Current liabilities:
Accounts payable		$11,912		$12,328
Accrued expenses and other current liabilities		59,314		62,658
Other current liability - LG Chem		38,783		37,704
Lease liability		224		—
Deferred revenue		—		1,286
Deferred royalty obligation, current		1,590		1,541
Total current liabilities		111,823		115,517
Long-term liabilities:
Deferred royalty obligation		107,934		108,269
Lease liability, non-current		3,839		3,938
Total liabilities		223,596		227,724
Commitments and contingencies (Note 13)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 150,000 and 150,000 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively. Liquidation preference of $150,000 as of March 31, 2025.		144,142		142,820
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024		—		—
Common stock, $0.001 par value: 120,000,000 shares authorized; 63,494,892 and 62,390,654 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively		62		61
Additional paid-in capital		1,223,772		1,177,045
Accumulated other comprehensive (loss)		(51)		(39)
Accumulated deficit		(1,204,836)		(1,155,338)
Total stockholders’ equity		18,947		21,729
Total liabilities, convertible preferred stock and stockholders’ equity		$386,685		$392,273

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.